Pfizer Inc (NYSE:PFE) attains the conditional approval for Cancer treatment, Xalkori (crizotinib)
Pfizer Inc (NYSE:PFE), one of the U.S largest healthcare company, has introduced the treatment of a severe disease known as non-small cell lung cancer (NSCLC), in the UK. The treatment has been named Xalkori (crizotinib).
This drug gained approval in Europe under a conditional licence for patients with previously treated ALK-positive advanced NSCLC patients. The oral drug becomes the primary specific treatment for this patient subgroup to reach the market. This treatment will play a key role for such patients, stated by the Pfizer Oncology UK’s medical director Dr David Montgomery.
According to him, Crizotinib is a latest personalized cure for patients who suffer that kind of lung cancer. It indicates that the company is highly committed to improve the understanding of the underlying genetic drivers of diseases in order to help those people who need the treatment, he added.
Pfizer Inc. (NYSE:PFE) hit 15.69% as their profit margin for the last twelve months and had an operating margin of 20.12%. Evaluating management effectiveness, return on equity was maintained at 11.05% in last twelve months. Return on assets for Intel was 5.03%. In the previous 52 weeks the price has traded between $19.73 – $26.09. The last session’s volume of 28.28 million shares competed with the average daily trading volume of 31.31 million shares.
Within the industry, Merck & Co., Inc. (NYSE:MRK) had a 14.41% profit margin in the last twelve months and an operating margin at 18.79%. Return on equity for this company was 12.21% in the last twelve months. Return on assets was 6.48%. In the last year the stock has moved within a range of $34.86 – $48.00. The last session’s volume of 11.62 million shares competed with the average daily trading volume of 11.58 million shares.
Johnson & Johnson (NYSE:JNJ) recorded a profit margin of 12.39% for the prior 12 months and an operating margin at 16.68%. Return on equity for this stock was 13.58% while return on assets was 7.08%.
Within the industry, Bristol Myers Squibb Co. (NYSE:BMY) had a 14.87% profit margin in the last twelve months and an operating margin at 18.12%. Return on equity for this company was 12.37% in the last twelve months. Return on assets was 8.25%.